Little Green Pharma Ltd (ASX: LGP) has welcomed recent success at the 60th Australian National Export Awards in the International Health category. This success follows the company’s recent win at the WA Export Awards for the same category.
The Australian National Export Awards are designed to honour the achievements of remarkable Australian exporters.
I am extremely proud of our team at Little Green Pharma. The manufacture and exportation of medicinal cannabis products to Europe is a complex regulatory and logistical exercise, and this award is due recognition of the extraordinary efforts by the Little Green Pharma team in exporting into so many countries, and against a very competitive field of excellent Australian health exporters. It is such a thrill and honour to be recognised for this prestigious award,” CEO and Managing Director of Little Green Pharma, Fleta Solomon, said.
About LGP
Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.
The company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500 sq. m cultivation and 4,000 sq. m GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~three tonnes of medicinal cannabis biomass per annum.
Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical- grade cannabis products to Australian, European and overseas markets.
The company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.